Lexaria Bioscience Corp. (NASDAQ: LEXX) Expects Study Results to Show its Patented Tech’s Value in Treating Hypertension Patients
Lexaria Bioscience is preparing to file an Investigational New Drug application with the U.S. Food and Drug Administration for its patented technology’s use in treating hypertension (high blood pressure) The company has completed multiple studies of the benefits of DehydraTECH(TM), in combination with cannabidiol to combat hypertension conditions and consequentially benefit cardiovascular patients Lexaria recently announced that it is nearing completion of a third human study in which the company expects to further explore whether DehydraTECH-CBD successfully treats high pulmonary blood pressure A comprehensive six-week human clinical study is expected to begin soon Lexaria Bioscience (NASDAQ: LEXX) is nearing completion…

















